Pay in 4 interest-free payments of $6.77 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
A University of British Columbia study published in JAMA the first large look at non-diabetic people taking these drugs for weight loss found GLP-1 users had a 3.67 times higher risk of gastroparesis than people on an older weight-loss drug
The treatment is also effective in those with type 2 diabetes and clinically-diagnosed obesity
Can I switch back to semaglutide if tirzepatide doesnt work
Tirzepatide: Weight Loss: Studies show an average weight loss of 21% to 25% of body weight
According to the MHRA/EMC Summary of Product Characteristics, the most common adverse effects include: Nausea very common (affects more than 1 in 10 people), often most pronounced when starting treatment or increasing the dose Vomiting very common, typically improves as the body adjusts to the medication Diarrhoea very common Abdominal pain or discomfort common (affects up to 1 in 10 people) Decreased appetite common Constipation common Dyspepsia (indigestion) common, including bloating and flatulence These gastrointestinal effects are generally most prominent during the initial weeks of treatment and often diminish over time as the body adapts
US$ 27.28
US$ 29.05
US$ 22.34
US$ 26.09
US$ 29.59
US$ 25.84
